Aims
-Development of molecules targeting tyrosine-kinase transmembrane receptors (EGFR and others). The new molecules that are being assayed in patients are defined by increased affinity for their cognate receptors and in some cases by their broader activity. Phase I clinical trial are presently ongoing using AE788 (antiEGFR, antiHER2 antiVEGFR) and BMS-626 (antiEGFR and antiHER2).
-Performing studies in order to determine the feasibility of using different agents targeting molecules involved in key aspects of the transformation process. Several phase I clinical trials are launched using compounds directed against SRC, TGFbeta, IFGR, HDAC or CHK among others. Our goal is consolidate our privileged position as European leaders in the field.
- Design and test in the laboratory new approaches for cancer treatment through the combination of drugs able to interfere with different signal transduction pathways: Two of these combinations: EGFR inhibitors plus compounds blocking TOR activation and IGFR1 inhibitors plus anti TOR agents are currently being tested in clinical trials.
-Analysis of the pharmacodynamics of the different compounds we are presently testing by using experimental models. We have especial interest in the development of new biomarkers to establish the therapeutic potential of these new drugs. We make use of proteomic and genetic tools as well as in vivo imaging techniques.
-Study the response to conventional chemotherapy. Tissue samples are obtained from treated patients and analyzed trying to establish a correlation between the gene profile and the resistance or sensitivity to the different treatments
-We are participating in Phase III clinical trials using drugs developed at IR-HUVH.